Provided by Tiger Trade Technology Pte. Ltd.

Atara Biotherapeutics

9.75
+0.35003.72%
Post-market: 9.750.00000.00%19:22 EDT
Volume:47.60K
Turnover:454.16K
Market Cap:97.87M
PE:-8.20
High:9.79
Open:9.41
Low:9.05
Close:9.40
52wk High:19.15
52wk Low:3.92
Shares:10.04M
Float Shares:4.62M
Volume Ratio:0.79
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1889
EPS(LYR):2.57
ROE:-2014.86%
ROA:-24.14%
PB:-2.65
PE(LYR):3.79

Loading ...

Atara Partner Pierre Fabre Resubmits Tabelecleucel BLA to FDA

Reuters
·
Sep 30

Atara Biotherapeutics Reports That the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

THOMSON REUTERS
·
Sep 30

Jeito Capital Promotes Pascal Touchon to Partner

Reuters
·
Sep 08

Atara Biotherapeutics Director Brian Cherry Acquires 104,166 Common Shares for $999,993.60

Reuters
·
Sep 05

Mizuho Securities Remains a Buy on Atara Biotherapeutics (ATRA)

TIPRANKS
·
Aug 31

Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer

Reuters
·
Aug 17

Traws Pharma Q2 Revenue Falls to Zero on Licensing Termination; Net Loss Widens

Reuters
·
Aug 15

Atara Biotherapeutics’ Executive Turnover and Workforce Cuts Elevate Execution Risk and Threaten Strategic Progress

TIPRANKS
·
Aug 14

Sensus Healthcare Q2 Revenue Misses Estimates as Unit Sales Fall

Reuters
·
Aug 14

Atara Biotherapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate

Benzinga Earnings
·
Aug 13

Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition

Reuters
·
Aug 13

Atara Biotherapeutics Q2 EPS USD -0.32

THOMSON REUTERS
·
Aug 13

Atara Biotherapeutics: ‍2026 Operating Expenses are Expected to Decline Significantly Year-over-Year

THOMSON REUTERS
·
Aug 13

Atara Biotherapeutics Q2 Revenue USD 630 Thousand

THOMSON REUTERS
·
Aug 13

Sight Sciences Names Kashif Rashid Chief Legal Officer, Replacing Jeremy Hayden

Reuters
·
Aug 10

Atara Biotherapeutics, Inc. Expected to Post a Loss of 31 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Imagenebio Names Yanina Grant-huerta CFO

Reuters
·
Jul 24

Atara Biotherapeutics Files Initial Beneficial Ownership Statement for Interim CFO Kevin Sarney

Reuters
·
Jul 07

Atara Biotherapeutics Names Kevin Sarney Interim CFO

Reuters
·
Jun 27